Roche announces data from its Phase III OCARINA II study of OCREVUS

Roche announced data from the Phase III OCARINA II study of OCREVUS. Results showed near-complete suppression of clinical relapses and brain lesions in people with relapsing or primary progressive multiple sclerosis which reinforce the potential benefits of this investigational formulation. The data will be presented as an oral presentation at the 76th American Academy of Neurology Annual Meeting taking place April 13-18 in Denver. Updated, longer-term results showed that OCREVUS SC injection resulted in near-complete suppression of relapse activity and MRI up to 48 weeks with an ARR of 0.04, and most patients having no T1 gadolinium-enhancing lesions and no new/enlarging T2 lesions. Additionally, in exploratory patient reported outcome measures patients reported a high level of satisfaction and convenience with OCREVUS SC injection. Additional data continued to show that the safety profile of OCREVUS SC injection was consistent with the well-established safety profile of OCREVUS IV infusion. No new safety signals were identified for OCREVUS SC. The most common adverse events in the OCREVUS SC group were injection reactions, including erythema, pain, swelling and pruritus, all of which were either mild or moderate and none of which led to treatment withdrawal.